Point72 Asset Management L.P. Sells 197,019 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Point72 Asset Management L.P. lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 83.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,817 shares of the company's stock after selling 197,019 shares during the period. Point72 Asset Management L.P. owned 0.08% of Amphastar Pharmaceuticals worth $1,884,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Aurora Investment Counsel grew its stake in shares of Amphastar Pharmaceuticals by 0.4% in the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company's stock worth $2,654,000 after acquiring an additional 232 shares during the period. GAMMA Investing LLC raised its stake in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $32,000 after purchasing an additional 273 shares during the period. Crossmark Global Holdings Inc. grew its stake in Amphastar Pharmaceuticals by 2.5% during the second quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company's stock valued at $452,000 after acquiring an additional 275 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock valued at $85,000 after buying an additional 301 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after purchasing an additional 309 shares during the last quarter. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Up 0.4 %

NASDAQ:AMPH traded up $0.17 during midday trading on Tuesday, reaching $44.00. The company had a trading volume of 183,151 shares, compared to its average volume of 398,416. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 0.87 and a beta of 0.78. The stock's fifty day simple moving average is $47.41 and its 200-day simple moving average is $44.62.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $386,523.30. Following the transaction, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. The trade was a 7.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard K. Prins sold 5,000 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total transaction of $244,000.00. Following the sale, the director now owns 31,471 shares of the company's stock, valued at approximately $1,535,784.80. This trade represents a 13.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,533 shares of company stock valued at $1,238,842. Insiders own 27.10% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on AMPH. StockNews.com cut Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $60.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.